• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CVS Health appoints Michael F. Mahoney to its Board of Directors

    9/21/23 6:45:00 AM ET
    $BSX
    $CVS
    Medical/Dental Instruments
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $BSX alert in real time by email

    WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.

    CVS Health (PRNewsFoto/CVS Health)

    "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued focus on strengthening our engagement with consumers to improve their health and well-being."

    Mahoney became the CEO of Boston Scientific Corporation in 2012 and became Chairman of the company's Board of Directors in 2016. With more than 45,000 global employees, Boston Scientific reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation, urology, and women's health.

    "We're extremely pleased to have Mike join the Board," said Roger N. Farah, Independent Chair of the Board of CVS Health. "His knowledge and insight will be a tremendous asset, as will his background in leading the development of innovative solutions for patients."

    Mahoney's career spans more than 25 years of success building market-leading medical device, capital equipment and health care IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson. Mahoney previously was President and CEO of Global Healthcare Exchange, a leading medical supply chain solutions company. For the first 12 years of his career, he advanced through a series of leadership roles at General Electric Medical Systems, including as General Manager of its Healthcare Information Technology business.

    "CVS Health and Boston Scientific share many common goals, with a primary focus on making a real difference for the people and patients we serve," Mahoney said. "I hope that my experience within the health care industry will help me work with the Board and the management team to support and advance CVS Health's strategy."

    Mahoney serves on the Board of the Boys & Girls Club of Boston and as the chair of the Board of Governors of the Boston College Chief Executives Club. He previously served on the Board of Directors of Baxter International Inc., a multinational health care company. He earned his B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

    About CVS Health

    CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

    Media contact

    Ethan Slavin

    860-273-6095

    [email protected]

    Investor contact

    Larry McGrath

    800-201-0938

    [email protected] 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-appoints-michael-f-mahoney-to-its-board-of-directors-301934025.html

    SOURCE CVS Health

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    CVS Health Corporation
    $CVS
    8/18/2025$79.00Neutral → Buy
    UBS
    CVS Health Corporation
    $CVS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    CVS Health Corporation
    $CVS
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    CVS Health Corporation
    $CVS
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    CVS Health Corporation
    $CVS
    1/30/2025Hold → Buy
    Edward Jones
    More analyst ratings

    $BSX
    $CVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boston Scientific upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Boston Scientific from Perform to Outperform and set a new price target of $125.00

    9/8/25 8:36:41 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded CVS Health from Neutral to Outperform and set a new price target of $82.00

    8/14/25 8:02:24 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $BSX
    $CVS
    SEC Filings

    View All

    $BSX
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BSX
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BSX
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    9/22/25 4:19:42 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Boston Scientific Corporation filed SEC Form 8-K: Leadership Update

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    9/4/25 4:07:43 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Boston Scientific Corporation

    144 - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    9/2/25 4:08:09 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    2/19/25 12:35:35 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/13/25 4:32:41 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    BetterInvesting™ Magazine Update on Vertiv Holdings Co. (NYSE: VRT) and CVS Health Corp. (NYSE: CVS)

    TROY, Mich., Sept. 30, 2025 /PRNewswire/ -- Vertiv Holdings Co.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Vertiv Holdings Co. (NYSE:VRT) as worthy of further study and has named the company its "Stock to Study" for the December 2025 issue for investors' informational and educational use. The fundamental data is eye-opening; investors can view Vertiv's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/study/ss

    9/30/25 10:20:00 AM ET
    $CVS
    $VRT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Industrial Machinery/Components
    Technology

    CVS Health to hold third quarter 2025 earnings conference call

    WOONSOCKET, R.I., Sept. 30, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, October 29th, 2025, at 8:00 a.m. ET to discuss third quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025,

    9/30/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Omnicare Initiates Voluntary Chapter 11 Process

    Company Intends to Use Process to Implement a Standalone Restructuring or Sale Strategy Remains Focused on Delivering Safe and Reliable Pharmacy Services to All Customers WOONSOCKET, R.I., Sept. 22, 2025 /PRNewswire/ -- Omnicare, LLC, a subsidiary of CVS Health (NYSE:CVS), today announced it has initiated a voluntary court-supervised Chapter 11 process to resolve issues related to its recent litigation in the U.S. District Court for the Southern District of New York. The Company also intends to use this process to address other financial challenges facing the broader long-term care pharmacy industry and to evaluate its restructuring options, including the implementation of a standalone rest

    9/22/25 1:01:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 50,000 shares at a strike of $26.15 and sold $5,271,416 worth of shares (50,000 units at $105.43) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    9/3/25 4:17:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    EVP and Group President Shah Prem S covered exercise/tax liability with 6,995 shares, decreasing direct ownership by 10% to 60,632 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    9/2/25 4:42:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Exp & Tech Officer Mandadi Tilak covered exercise/tax liability with 12,834 shares, decreasing direct ownership by 17% to 63,952 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    9/2/25 4:40:46 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $BSX
    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS Health to hold third quarter 2025 earnings conference call

    WOONSOCKET, R.I., Sept. 30, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, October 29th, 2025, at 8:00 a.m. ET to discuss third quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025,

    9/30/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., Sept. 17, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 3, 2025, to holders of record on October 23, 2025. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and prima

    9/17/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results

    MARLBOROUGH, Mass., Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025, beginning at 8:30 a.m. ET. The Investor Day meeting will be held in hybrid format with a simultaneous online webcast. Investors and other interested parties may register for the webcast by visiting the events section on the company's investor website at https://investors.bostonscientific.com. A replay and summary materials from the presentations wi

    9/2/25 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

    WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

    4/8/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    4/3/25 11:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care